Press Releases

VBL Presents Positive Preclinical Data on Immune Modulator in Rheumatoid Arthritis at EULAR Annual Meeting

June 17, 2010

VBL Therapeutics to Present Data on VB-201 for Rheumatoid Arthritis at EULAR Annual Meeting

June 10, 2010

Keystone Symposium Highlights Positive Preclinical Data on Novel Immune Modulator

June 7, 2010

VBL Therapeutics to Present Anti-Inflammatory Properties of VBL-201 at Keystone Symposium

June 1, 2010

VBL Therapeutics Announces Positive Preclinical Data for VB-201 against Psoriasis -- First in New Class of Orally Available Anti-Inflammatory Compounds

May 7, 2010

VBL Therapeutics Announces Preclinical and Clinical Data Demonstrating Substantial Tumor Reduction and Stable Disease Achieved with First-in-Class Vascular Disruptive Agent in Advanced Cancers

April 19, 2010

VBL Therapeutics to Present Data from VB-201 and VB-111 at Prominent Cancer Research and Dermatology Medical Meetings

April 13, 2010

VBL Therapeutics to Present at 28th Annual J.P. Morgan Healthcare Conference

January 6, 2010

VBL Therapeutics Initiates Phase 2 Clinical Trial of VB-201 in Patients with Psoriasis

January 5, 2010

Vascular Biogenics Ltd. presented with the Frost & Sullivan 2008 European Gene Expression Targeting Platform Technology Innovation Award

September 18th, 2008